Internal Quality Assurance Program for ERBB2 (HER2) Testing Improves the Selection of Breast Cancer Patients for Treatment with Trastuzumab.

Détails

ID Serval
serval:BIB_8AE4AB8C6384
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Internal Quality Assurance Program for ERBB2 (HER2) Testing Improves the Selection of Breast Cancer Patients for Treatment with Trastuzumab.
Périodique
Pathology Research International
Auteur(s)
Martin V., Camponovo A., Ghisletta M., Bongiovanni M., Mazzucchelli L.
ISSN
2042-003X (Electronic)
ISSN-L
2042-003X
Statut éditorial
Publié
Date de publication
2012
Volume
2012
Pages
261857
Langue
anglais
Notes
Publication types: Journal ArticlePublication Status: ppublish
Résumé
International guidelines for ERBB2 (HER2) testing procedures in breast cancer patients highlight the importance of external quality control. In contrast, internal quality assurance programs have been poorly defined, and their clinical significance has not yet been investigated. We developed a quality assurance scheme by performing HER2 FISH on 724 patients randomly selected out of 1996 patients with breast cancer presenting at our institute. We collected samples monthly for tissue microarray analysis and correlated HER2 gene status with IHC scores. The concordance was excellent (κ = 0.92, P < 0.0001). HER2 amplification characterized 25% of score 2+ but also 13% of score 1+, thus expanding the number of patients eligible for trastuzumab. Based on these findings, the FISH test is now recommended at our institution for score 1+ and 2+ patients. Adherence to internal assurance program improves patient selection and may lead to the definition of in-house tailored diagnostic algorithms different from those proposed in international guidelines.
Pubmed
Création de la notice
26/01/2015 10:42
Dernière modification de la notice
03/03/2018 19:10
Données d'usage